Profitability
Weight: 15%
F
5
- 5yr Avg ROIC -5.9%
- Operating Margin Trend -1.15 pp/yr
ZVRA
Zevra Therapeutics, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 30.0 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -13.4%
- 5yr Share-Count CAGR 17.8%
Growth Quality
Weight: 35%
B-
64
- 5yr Revenue CAGR 38.8%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 3/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -113.9%
- 5yr FCF/NI Conversion -0.03x
Balance Sheet
Weight: 10%
A+
96
- Net Debt / EBITDA -1.29x
- Interest Coverage (EBIT/Int) 11.87x
- Altman Z-Score 5.63
Stability
Weight: 5%
A-
83
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 7
- Negative-Revenue Years (5) 2/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.2 of 2 gurus held; 1 new buy; 1 trimmed.
- Holders
- 2 +1
- Avg Δ position
- -2.0%
- New buys
- 1
- Full exits
- 0